ATE500814T1 - Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphat - Google Patents
Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphatInfo
- Publication number
- ATE500814T1 ATE500814T1 AT05717745T AT05717745T ATE500814T1 AT E500814 T1 ATE500814 T1 AT E500814T1 AT 05717745 T AT05717745 T AT 05717745T AT 05717745 T AT05717745 T AT 05717745T AT E500814 T1 ATE500814 T1 AT E500814T1
- Authority
- AT
- Austria
- Prior art keywords
- phosphate
- polyol
- composition containing
- sugar
- containing chitosan
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000010452 phosphate Substances 0.000 title abstract 3
- 229920001661 Chitosan Polymers 0.000 title abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 2
- 229920005862 polyol Polymers 0.000 title 1
- 150000003077 polyols Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Consolidation Of Soil By Introduction Of Solidifying Substances Into Soil (AREA)
- Polyurethanes Or Polyureas (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0403938.4A GB0403938D0 (en) | 2004-02-21 | 2004-02-21 | Chitosan containing solution |
| PCT/GB2005/000592 WO2005079749A2 (en) | 2004-02-21 | 2005-02-18 | Chitosan containing solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500814T1 true ATE500814T1 (de) | 2011-03-15 |
Family
ID=32040183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05717745T ATE500814T1 (de) | 2004-02-21 | 2005-02-18 | Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphat |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080248991A1 (de) |
| EP (1) | EP1722759B1 (de) |
| AT (1) | ATE500814T1 (de) |
| DE (1) | DE602005026783D1 (de) |
| ES (1) | ES2420356T3 (de) |
| GB (1) | GB0403938D0 (de) |
| WO (1) | WO2005079749A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1375301A (en) | 1999-11-15 | 2001-05-30 | Bio Syntech Canada Inc | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| US20030158302A1 (en) | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
| DE60003459T2 (de) * | 1999-12-09 | 2004-05-06 | Biosyntech Canada Inc., Laval | Mineral-polymer hybrid-zusammensetzung |
| DK1294414T3 (da) * | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv |
| EP1790351A4 (de) * | 2004-09-15 | 2009-11-04 | Otsuka Pharma Co Ltd | Permukosale zusammensetzung und verfahren zur verbesserung der permukosalen absorption |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| WO2007059605A1 (en) * | 2005-11-04 | 2007-05-31 | Bio Syntech Canada Inc. | Composition and method for efficient delivery of nucleic acids to cells using chitosan |
| EP2057982A1 (de) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasale Zusammensetzungen |
| CL2008000156A1 (es) | 2008-01-18 | 2008-08-01 | Igloo Zone Chile S A | Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel. |
| WO2010118516A1 (en) * | 2009-04-14 | 2010-10-21 | Globe Laboratories Inc. | Compositions for sublingual drug delivery and methods of use thereof |
| DE102009024542A1 (de) | 2009-06-10 | 2010-12-16 | Arivine Pharma Ag | Zusammensetzungen auf Basis von Chitosan-Oligosacchariden |
| WO2012107573A1 (en) * | 2011-02-10 | 2012-08-16 | Moberg Derma Ab | Novel formulations for dermal, transdermal and mucosal use 3 |
| EP2854764B1 (de) | 2012-06-05 | 2018-12-12 | Neuroderm Ltd | Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon |
| US20150231130A1 (en) | 2012-07-26 | 2015-08-20 | Wockhardt Limited | Pharmaceutical composition comprising diamorphine for intranasal administration |
| TWI624270B (zh) * | 2013-01-17 | 2018-05-21 | 財團法人工業技術研究院 | 藥物組合物 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9192574B2 (en) | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
| US9192692B2 (en) | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan stenting paste |
| US9480828B2 (en) | 2013-11-14 | 2016-11-01 | Gyrus Acmi, Inc. | Treatment method for the inferior turbinate |
| US20180133147A1 (en) * | 2013-12-19 | 2018-05-17 | Novartis Ag | Drug Delivery Systems |
| SG11201702614SA (en) * | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| NL2022788B1 (en) * | 2019-03-22 | 2020-09-28 | No Ceuticals B V | Chitosan nitrate for use as a nitric oxide donor (NO donor) |
| KR102415342B1 (ko) * | 2021-07-07 | 2022-07-04 | 주식회사 메디팹 | 다중 가교된 온도감응성 하이드로겔 제조용 조성물 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| GB9414966D0 (en) * | 1994-07-26 | 1994-09-14 | Danbiosyst Uk | Pharmaceutical compositions for the nasal administration of antiviral agents |
| CA2212300A1 (en) * | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
| AU1375301A (en) * | 1999-11-15 | 2001-05-30 | Bio Syntech Canada Inc | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
| CA2429165A1 (en) * | 2000-11-15 | 2002-05-23 | Bio Syntech Canada Inc. | Filler composition for soft tissue augmentation and reconstructive surgery |
-
2004
- 2004-02-21 GB GBGB0403938.4A patent/GB0403938D0/en not_active Ceased
-
2005
- 2005-02-18 WO PCT/GB2005/000592 patent/WO2005079749A2/en not_active Ceased
- 2005-02-18 DE DE602005026783T patent/DE602005026783D1/de not_active Expired - Lifetime
- 2005-02-18 EP EP05717745A patent/EP1722759B1/de not_active Expired - Lifetime
- 2005-02-18 US US10/598,212 patent/US20080248991A1/en not_active Abandoned
- 2005-02-18 AT AT05717745T patent/ATE500814T1/de not_active IP Right Cessation
- 2005-02-18 ES ES05717745T patent/ES2420356T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1722759B1 (de) | 2011-03-09 |
| WO2005079749A2 (en) | 2005-09-01 |
| GB0403938D0 (en) | 2004-03-24 |
| US20080248991A1 (en) | 2008-10-09 |
| WO2005079749A3 (en) | 2006-03-23 |
| EP1722759A2 (de) | 2006-11-22 |
| ES2420356T3 (es) | 2013-08-23 |
| DE602005026783D1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005026783D1 (en) | Erphosphat oder ein polyolphosphat | |
| DE502004007735D1 (en) | Flächiges implantat | |
| TWI341201B (en) | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | |
| BRPI0507440A (pt) | fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas | |
| IS7543A (is) | Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær | |
| DK1768490T3 (da) | Systemer og fremgangsmåder til ex-vivo-organpleje | |
| ATE510558T1 (de) | Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen | |
| ZA200801511B (en) | Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases | |
| WO2008045021A3 (en) | Blood compatible nanomaterials and methods of making and using the same | |
| BR0307564A (pt) | Derivados de nicotinamida úteis como inibidores de pde4 | |
| DE602004022554D1 (de) | Thermische behandlung einer implantierbaren medizinischen arzneimittel-elutions-vorrichtung | |
| NO20083026L (no) | Terapeutisk middel for diabetes | |
| WO2009091994A3 (en) | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof | |
| ATE448206T1 (de) | Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen | |
| NO20073574L (no) | Triazolsubstituerte aminobenzofenonforbindelser | |
| NO20050569D0 (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| WO2004072265A3 (en) | Methods for monitoring drug activities in vivo | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| ZA200707560B (en) | 5-phenyl-pentanoc acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | |
| NO20073631L (no) | Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel | |
| WO2004091591A3 (fr) | Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives | |
| DK2046813T3 (da) | Proteinbindende methotrexat-derivater og lægemiddel indeholdende disse | |
| UA86399C2 (ru) | Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза | |
| ATE444754T1 (de) | Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse | |
| ATE375152T1 (de) | Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |